Company Registration No. 11591997 (England and Wales)
Genome Ltd
Unaudited accounts
for the year ended 30 April 2025
Genome Ltd
Unaudited accounts
Contents
Genome Ltd
Company Information
for the year ended 30 April 2025
Directors
Pawel Gorski
Stacey Hatton
Michal Gorski
Company Number
11591997 (England and Wales)
Registered Office
Wharf House Victoria Quays
Wharf Street
Sheffield
S2 5SY
United Kingdom
Accountants
Shipleys Tax - Chartered Accountants
32 Park Cross Street
Leeds
West Yorkshire
LS1 2QH
Genome Ltd
Statement of financial position
as at 30 April 2025
Tangible assets
7,310
2,510
Cash at bank and in hand
60,621
62,964
Creditors: amounts falling due within one year
(399,259)
(334,568)
Net current liabilities
(322,251)
(270,469)
Net liabilities
(314,941)
(267,959)
Called up share capital
100
100
Profit and loss account
(315,041)
(268,059)
Shareholders' funds
(314,941)
(267,959)
For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 7 January 2026 and were signed on its behalf by
Michal Gorski
Director
Company Registration No. 11591997
Genome Ltd
Notes to the Accounts
for the year ended 30 April 2025
Genome Ltd is a private company, limited by shares, registered in England and Wales, registration number 11591997. The registered office is Wharf House Victoria Quays, Wharf Street, Sheffield, S2 5SY, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws.
Deferred tax assets and liabilities are not discounted.
The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are recognised in the profit and loss account when due.
Basic financial instruments are recognised at amortised cost, except for investments in non-convertible preference and non-puttable ordinary shares which are measured at fair value, with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value with changes recognised in profit or loss.
Genome Ltd
Notes to the Accounts
for the year ended 30 April 2025
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
The financial statements have been prepared on a going concern basis. The directors have assessed the company's ability to continue operating for the foreseeable future, considering relevant factors such as current and expected financial performance, cash flow forecasts, and access to funding. Based on this assessment, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for at least 12 months from the date of approval of the financial statements.
Judgments in applying accounting policies and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
4
Tangible fixed assets
Fixtures & fittings
Computer equipment
Total
Cost or valuation
At cost
At cost
At 1 May 2024
475
13,876
14,351
Additions
1,217
5,057
6,274
At 30 April 2025
1,692
18,933
20,625
At 1 May 2024
470
11,371
11,841
Charge for the year
192
1,282
1,474
At 30 April 2025
662
12,653
13,315
At 30 April 2025
1,030
6,280
7,310
At 30 April 2024
5
2,505
2,510
Amounts falling due within one year
Accrued income and prepayments
1,987
1,135
Genome Ltd
Notes to the Accounts
for the year ended 30 April 2025
6
Creditors: amounts falling due within one year
2025
2024
Amounts owed to group undertakings and other participating interests
193,684
193,684
Other creditors
76,309
27,765
Loans from directors
121,713
107,794
7
Average number of employees
During the year the average number of employees was 4 (2024: 3).